JP2025072466A5 - - Google Patents
Info
- Publication number
- JP2025072466A5 JP2025072466A5 JP2025015899A JP2025015899A JP2025072466A5 JP 2025072466 A5 JP2025072466 A5 JP 2025072466A5 JP 2025015899 A JP2025015899 A JP 2025015899A JP 2025015899 A JP2025015899 A JP 2025015899A JP 2025072466 A5 JP2025072466 A5 JP 2025072466A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administration
- subject
- administered
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752832P | 2018-10-30 | 2018-10-30 | |
| US62/752,832 | 2018-10-30 | ||
| US201962860565P | 2019-06-12 | 2019-06-12 | |
| US62/860,565 | 2019-06-12 | ||
| US201962881137P | 2019-07-31 | 2019-07-31 | |
| US62/881,137 | 2019-07-31 | ||
| JP2021548551A JP7630435B2 (ja) | 2018-10-30 | 2019-10-30 | 抗ｃｄ１２３免疫複合体を用いた治療法 |
| PCT/US2019/058824 WO2020092533A2 (en) | 2018-10-30 | 2019-10-30 | Methods of treatment using anti-cd123 immunoconjugates |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548551A Division JP7630435B2 (ja) | 2018-10-30 | 2019-10-30 | 抗ｃｄ１２３免疫複合体を用いた治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025072466A JP2025072466A (ja) | 2025-05-09 |
| JP2025072466A5 true JP2025072466A5 (https=) | 2026-02-16 |
Family
ID=70464182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548551A Active JP7630435B2 (ja) | 2018-10-30 | 2019-10-30 | 抗ｃｄ１２３免疫複合体を用いた治療法 |
| JP2025015899A Pending JP2025072466A (ja) | 2018-10-30 | 2025-02-03 | 抗ｃｄ１２３免疫複合体を用いた治療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548551A Active JP7630435B2 (ja) | 2018-10-30 | 2019-10-30 | 抗ｃｄ１２３免疫複合体を用いた治療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200157228A1 (https=) |
| EP (1) | EP3873524B8 (https=) |
| JP (2) | JP7630435B2 (https=) |
| KR (1) | KR20210087951A (https=) |
| CN (2) | CN118557748A (https=) |
| AU (1) | AU2019370291B2 (https=) |
| CA (1) | CA3117493A1 (https=) |
| IL (1) | IL282685A (https=) |
| MA (1) | MA54088A (https=) |
| SG (1) | SG11202103999VA (https=) |
| TW (1) | TWI870363B (https=) |
| WO (1) | WO2020092533A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220004669A (ko) * | 2019-04-29 | 2022-01-11 | 이뮤노젠 아이엔씨 | 항-cd123 면역접합체를 포함하는 치료적 조합물 |
| US20250345449A1 (en) * | 2024-05-10 | 2025-11-13 | Immunogen, Inc. | Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| US8163279B2 (en) * | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
| BRPI0907046A2 (pt) | 2008-01-18 | 2015-07-28 | Medimmune Llc | Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo |
| EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
| CN107753954A (zh) * | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| SG11201509043RA (en) * | 2013-05-14 | 2015-12-30 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| EP3041846B1 (en) * | 2013-09-02 | 2018-11-07 | Hangzhou Dac Biotech Co., Ltd | Novel cytotoxic agents for conjugation of drugs to cell binding molecule |
| TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| SMT202000614T1 (it) | 2015-06-29 | 2021-01-05 | Immunogen Inc | Coniugati di anticorpi ingegnerizzati con cisteina |
| AU2016285552B2 (en) | 2015-06-29 | 2022-10-13 | Immunogen, Inc. | Anti-CD123 antibodies and conjugates and derivatives thereof |
| WO2018098258A2 (en) * | 2016-11-23 | 2018-05-31 | Immunogen, Inc. | Selective sulfonation of benzodiazepine derivatives |
| TW202021618A (zh) * | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
-
2019
- 2019-10-30 MA MA054088A patent/MA54088A/fr unknown
- 2019-10-30 JP JP2021548551A patent/JP7630435B2/ja active Active
- 2019-10-30 CN CN202410406681.5A patent/CN118557748A/zh active Pending
- 2019-10-30 KR KR1020217014003A patent/KR20210087951A/ko active Pending
- 2019-10-30 CN CN201980073676.4A patent/CN113329768A/zh active Pending
- 2019-10-30 EP EP19878291.4A patent/EP3873524B8/en active Active
- 2019-10-30 AU AU2019370291A patent/AU2019370291B2/en active Active
- 2019-10-30 SG SG11202103999VA patent/SG11202103999VA/en unknown
- 2019-10-30 US US16/668,257 patent/US20200157228A1/en not_active Abandoned
- 2019-10-30 TW TW108139297A patent/TWI870363B/zh active
- 2019-10-30 WO PCT/US2019/058824 patent/WO2020092533A2/en not_active Ceased
- 2019-10-30 CA CA3117493A patent/CA3117493A1/en active Pending
-
2021
- 2021-04-27 IL IL282685A patent/IL282685A/en unknown
-
2022
- 2022-11-09 US US18/054,076 patent/US20230312735A1/en active Pending
-
2025
- 2025-02-03 JP JP2025015899A patent/JP2025072466A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025072466A5 (https=) | ||
| JP2006527193A5 (https=) | ||
| AU2015411525B2 (en) | Combination therapy | |
| JP2024518947A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2023542608A5 (https=) | ||
| CA3008749C (en) | Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin | |
| JP2019514974A5 (https=) | ||
| JP2021525735A5 (https=) | ||
| JP2021515017A5 (https=) | ||
| JP2021534165A5 (https=) | ||
| JP2022532865A5 (https=) | ||
| JP2023508496A5 (https=) | ||
| JP2023501375A5 (https=) | ||
| AU2020377981A1 (en) | Dosing regimen for anti-DLL3 agents | |
| JP2022513386A5 (https=) | ||
| JP2025508786A5 (https=) | ||
| JP2021523233A5 (https=) | ||
| JP2024530954A5 (https=) | ||
| JP2022541591A5 (https=) | ||
| JP2024069230A5 (https=) | ||
| JP2025515092A5 (https=) | ||
| JPWO2020250915A5 (https=) | ||
| JP2023500888A5 (https=) | ||
| JP2023500697A5 (https=) |